Market closed

Verrica Pharmaceuticals/$VRCA

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.

Ticker

$VRCA
Sector
Health Care
Trading on
NASDAQ

Industry

Pharmaceuticals
Headquarters
West Chester, United States

Employees

100
Website
www.verrica.com

VRCA Metrics

BasicAdvanced
$58M
-
-$1.83
1.46
-

$58M

1.46

$11.41

$0.61

720K

1.341

1.096

-134.951

-138.36

-7.93%

-71.41%

-2,059.89%

3.208

-0.85

-0.85

-0.496

187.45%

66.07%

-8.44%

7.87%

What the Analysts think about VRCA

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Verrica Pharmaceuticals stock.

VRCA Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

VRCA Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

VRCA News

AllArticlesVideos
Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire·1 month ago
Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan

Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan

GlobeNewsWire·1 month ago
Verrica Announces Pricing of $42.0 Million Public Offering

Verrica Announces Pricing of $42.0 Million Public Offering

GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $VRCA

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Verrica Pharmaceuticals stock?

Verrica Pharmaceuticals (VRCA) has a market cap of $58M as of January 15, 2025.

What is the P/E ratio for Verrica Pharmaceuticals stock?

The price to earnings (P/E) ratio for Verrica Pharmaceuticals (VRCA) stock is 0 as of January 15, 2025.

Does Verrica Pharmaceuticals stock pay dividends?

No, Verrica Pharmaceuticals (VRCA) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Verrica Pharmaceuticals dividend payment date?

Verrica Pharmaceuticals (VRCA) stock does not pay dividends to its shareholders.

What is the beta indicator for Verrica Pharmaceuticals?

Verrica Pharmaceuticals (VRCA) has a beta rating of 1.46. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.